Antidotes to haemorrhage: Recombinant factor VIIa

Best Practice and Research: Clinical Haematology

Volumn 17, Issue 1, 2004, Pages 183-197

  Kessler, Craig M ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Allogeneic; Autocatalysis; Myocardial infraction; Thrombogenic

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ACTIVATED PROTHROMBIN COMPLEX; ALLOANTIBODY; ANTIDOTE; ANTIFIBRINOLYTIC AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 13 CONCENTRATE; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; DANAPAROID; FIBROGAMIN; FONDAPARINUX; HEPARIN; HEPARIN LYASE; HEPARINOID; HIRUDIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PHYTOMENADIONE; PROTAMINE SULFATE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; UNINDEXED DRUG; WARFARIN; XIMELAGATRAN;

AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE DISEASE; BLEEDING DISORDER; BLOOD CLOTTING FACTOR 11 DEFICIENCY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DATA ANALYSIS; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DISEASE CONTROL; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG USE; EVIDENCE BASED MEDICINE; HEART INFARCTION; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; LIVER DYSFUNCTION; MULTIPLE ORGAN FAILURE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; STANDARDIZATION; THROMBOCYTE ANOMALY; THROMBOCYTOPENIA; THROMBOSIS; TRAUMATOLOGY; VENOUS THROMBOEMBOLISM;

EID: 2942687029     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2004.03.010     Document Type: Review

References (60)

1. Lusher I. Use of prothrombin complex concentrates in the management of bleeding in hemophiliacs with inhibitors-benefits and limitations. Seminars in Hematology 1994; 31: 49-52.
2. Ballard S, Buck J, et aL Tracing blood units to their recipients: results of a two-centre study. Transfusion 2003; 13: 127-130.
3. Allain JP. Transfusion risks of yesterday and of today. Transfusion clinique et biologique: Journalde la Societe francaise de transfusionsanguine 2003; 10: 1-5.
4. Houston F, Foster JD, Chong A, et al. Transmission of BSE by blood transfusion in sheep. Lancet 2000; 356: 999-1007.
5. Silimann CC, Bjornsen AJ, Wyman TH, et al. Plasma and lipids from stored platelets cause acute lung injury in an animal model. Transfusion 2003; 43: 633-640.
6. Popovsky MA, Chaplin HC & Moore SB. Transfusion-related acute lung injury: a neglected, serious complication of hemotherapy. Transfusion 1992; 32: 589-592.
7. Engoren MC, Habib RH, Zacharias A, et al. Effect of blood transfusion on long-term survival after cardiac operation. The Annals of Thoracic Surgery 2002; 74: 1180-1186.
8. Chiarugi M, Buccianti P, Disarli M, et al. Effect of blood transfusions on disease-free interval after rectal cancer surgery. Hepatogastroenterology 2000; 47: 1002-1005.
9. Van de Watering LM, Hermans J, Houbiers JG, et al. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation 1998; 97: 562-568.
10. Nicolaisen EM. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience. Blood Coagulation Fibrinolysis 1998; 9(supplement 1): S119-S123.
11. Hedner U & Erhardtsen E. Potential role of recombinant factor VIIa as a hemostatic agent. Clinical Advances Hematology Oncology 2003; 1: 112-119.
12. Aledort L. Activated prothrombin complex concentrates and recombinant factor VIIa in the bleeding patient: are they appropriate and safe? The Journal of Thoracic and Cardiovascularsurgery 2003; 126: 2112-2113.
13. Von Heymann C, Ziener S, Kox WJ, et al. Caveat against the use of feiba in combination with recombinant factor VIIa. The Journal of Thoracic and Cardiovascular Surgery 2003; 126: 1667-1668.
14. Monroe D, Hoffman M & Roberts HR. Platelets and thrombin generation. Arteriosclerosis, Thrombosis, and Vascular Biology 2002; 22: 1381-1389.
15. Monroe DM, Hoffman M, Oliver JA & Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. British Journal of Haematology 1997; 99: 542-547.
16. Wilbourn B, Harrison P Mackie IJ, Liesner R & Machin SJ. Activation of platelets in whole blood by recombinant factor VIIa by a thrombin-dependent mechanism. British Journal of Haematology 2003; 122: 651-661.
17. Kenet G, Lubetsky A, Luboshitz J & Martinowitz U. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven). Journal of Thrombosis and Haemostasis 2003; 1: 450-455.
18. Deveras RAE & Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Annals of Internal Medicine 2003; 137: 884-888.
19. Carr ME, Kuhn JG, Martin EJ, et al. Pseudoprolongation of the prothrombin time during treatment with recombinant factor VIIa for bleeding in a patient with a spontaneous factor VIII inhibitor. International Journal of Hemotology 2003; 77: 308-309.
20. Lusher JM, Roberts HR, Davignon G, et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia 1998; 4: 790-798.
21. Mariani G, Testa MG, et al. Use of recombinant activated factor VII in the treatment of congenital factor VII deficiencies. Vox Sang 1999; 77: 131-136.
22. Hay CRM, Negrier C & Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thrombosis and Haemostasis 1997; 79: 1463-1467.
23. Erhardtsen E, Nony P, Dechavanne M, et al. The effect of recombinant factor VIIa in healthy volunteers receiving acenocoumarol to an international normalized ratio above 2.0. Blood Coagul Fibrinolysis 1998; 9: 741-748.
24. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. New England Journal of Medicine 2003; 348: 1425-1434.
25. Francis CW, Berkowitz SD, Comp PC, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. The New England Journal of Medicine 2003; 349: 1703-1712.
26. Eriksson H, Wahlander K, Gustafsson D, et al. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. Journal of Thrombosis and Haemostosis 2003; 1: 41-47.
27. Schulman, S, Wahlander K, Lundstrom T, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. The New England Journal of Medicine, 349; 18: 1713-1721.
28. Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. The New England Journal of Medicine 2001; 345: 165-169.
29. Weitz JI & Crowther M. Direct thrombin inhibitors. Thrombosis Research 2002; 106: V275-V284.
30. Samama MM, Gerotziafas GT, Elalamy I, et al. Biochemistry and clinical pharmacology of new anticoagulant agents. Pothophysiology Haemost Thrombosis 2002; 32: 218-224.
31. Elg M, Carlsson S & Gustafsson D. Effect of activated prothrombin complex concentrate and recombinant factor VIIa on the bleeding time and on thrombus formation during anticoagulation with a direct thrombin inhibitor. Thrombosis Research 2001; 101: 145-157.
32. Dickneite G, Nicolay U, Friesen HJ, et al. Development of an anti-bleeding agent for recombinant hirudin induced skin bleeding in the pig. Thrombosis and Haemostasis 1998; 80: 192-198.
33. Bittl JA, Chairman BR, Reit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. American Heart Journal 2001; 142: 952-958.
34. Eikelboom JW, Anand SS, Malmberg K, et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000; 355: 1936-1942.
35. Zufferey R Laporte S, Quenet S, et al. Optimal low molecular weight heparin regimens in major orthopaedic surgery. A meta-analysis of randomized trials. Thrombosis and Haemostasis 2003; 90: 654-661.
36. Koch A, Bouges S, Ziegler S, et al. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention. Update of previous meta-analyses. The British Journal of Surgery 1997; 84: 750-759.
37. Chan S, Kong M, Minning DM, et al. Assessment of recombinant factor VIIa as an antidote for bleeding induced in the rabbit by low molecular weight heparin. Journal of Thrombosis and Haemostasis 2003; 1: 760-765.
38. Chong BH, Ismail F, Cade J, et al. Heparin induced thrombocytopenia: studies with a new low molecular weight heparinoid Org 10172. Blood 1989; 73: 1592-1596.
39. Farner B, Eichler R Kroll H, et al. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thrombosis and Haemostasis 2001; 85: 950-957.
40. Turpie AGG, Bauer KA, Eriksson BI, et al. Fondaparinux versus enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Archives of Internal Medicine 2002; 162: 1833-1840.
41. Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106: 2550-2554.
42. Ma Q, Jain S, Maddineni J, et al. Differential digestion of low molecular weight heparins by heparinase-1: implications in neutralization of the potential bleeding complications. Blood 2003; 3005: 102. abstract.
43. Chang LC, Liang JF, Lee F, et al. Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote: in vitro evaluation of efficacy and toxicity. AAPS Pharmaceutical Sciences 2001; 3: E18. Abstract.
44. Lassen MR, Davidson BL, Gallus A, et al. A phase II randomized, double-blind, five-arm, parallel-group, dose-response study of a new oral directly-acting factor Xa inhibitor, razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery. Blood 2003; 102: 15. Abstract.
45. Lincoff AM. clinical investigation of a tissue-factor inhibitor administered during percutaneous coronary revascularization: a randomized, double-blinded, dose-escalation trial assessing safety and efficacy of FFR-FVIIa in percutaneous transluminal coronary angioplasty (ASIS) trial. Journal of the American College of Cardiology 2000; 312: 36. Abstract.
46. Benedict CR, Ryan J, Wolitzky B, et al. Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. The Journal of Clinical Investigation 1991; 88: 1760-1765.
47. Feuerstein GZ, Patel A, Toomey JR, et al. Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats. Arteriosclerosis, Thrombosis, and Vascular Biology 1999; 19: 2554-2562.
48. Tengborn L & Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thrombosis and Haemostasis 1996; 75: 981-982.
49. Poon MC & d'Oiron E. Recombinant activated factor VII treatment of platelet-related bleeding disorders. International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group. Blood Coagul Fibrinolysis 2000; 11(Supplement 1): S55-S68.
50. D'Oiron R, Menart C, Trzeciak MC, et al. Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures. Thrombosis and Haemostasis 2000; 83: 637-638.
51. Chuansumrit A, Suwannuraks; M, Sri-Udomporn N, et al. Recombinant activated factor VII combined with local measures in preventing bleeding from invasive dental procedures in patients with Glanzmann thrombasthenia. Blood Coagul Fibrinolysis 2003; 14: 187-196.
52. Pozo AID, Jimenez-Yuste V, Villar A, et al. Successful thyroidectomy in a patient with Hermansky-Pudlak syndrome treated with recombinant activated factor VII and platelet concentrates. Blood Coagul Fibrinolysis 2002; 13: 551-553.
53. Stepinska A. Activated recombinant factor VII in bleeding management after therapy with IIb/IIIa inhibitor tirofiban. Thrombosis and Haemostasis 2002; 87: 355-356.
54. Ng HJ, Koh LP & Lee LH. Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin. Annals of Hematology 2003; 82: 257-258.
55. Kristensen J, Killander A, Hippe E, et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 1996; 26(supplement 1): 159-164.
56. Erhardtsen E. Ongoing NovoSeven trials. Intensive Care Medicine 2002; 28(supplement 2): 1472-1476.
57. Martinowitz U, Holcomb JB, Pusateri AE, et al. Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries. The Journal of Trauma Injury Infectious Critical Care 2001; 50: 721-729.
58. Schreiber MA, Holcomb JV, Hedner U, et al. The effect of recombinant factor VIIa on coagulopathic pigs with grade V liver injuries. The Journal of Trauma Injury Infectious Critical Care 2002; 53: 252-257.
59. Martinowitz U, Kenet G, Segal E, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. The Journal of Trauma 2001; 51: 431-438.
60. Friederich PW, Henny CP Messelink EJ, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectromy: a double-blind placebo-controlled randomised trial. Lancet 2003; 361: 201-205.